290 related articles for article (PubMed ID: 36774542)
1. Enhanced Endosomal Signaling and Desensitization of GLP-1R vs GIPR in Pancreatic Beta Cells.
Manchanda Y; Bitsi S; Chen S; Broichhagen J; Bernardino de la Serna J; Jones B; Tomas A
Endocrinology; 2023 Mar; 164(5):. PubMed ID: 36774542
[TBL] [Abstract][Full Text] [Related]
2. Diabetes and obesity treatment based on dual incretin receptor activation: 'twincretins'.
Skow MA; Bergmann NC; Knop FK
Diabetes Obes Metab; 2016 Sep; 18(9):847-54. PubMed ID: 27160961
[TBL] [Abstract][Full Text] [Related]
3. Differential importance of glucose-dependent insulinotropic polypeptide vs glucagon-like peptide 1 receptor signaling for beta cell survival in mice.
Maida A; Hansotia T; Longuet C; Seino Y; Drucker DJ
Gastroenterology; 2009 Dec; 137(6):2146-57. PubMed ID: 19766644
[TBL] [Abstract][Full Text] [Related]
4. Functional consequences of glucagon-like peptide-1 receptor cross-talk and trafficking.
Roed SN; Nøhr AC; Wismann P; Iversen H; Bräuner-Osborne H; Knudsen SM; Waldhoer M
J Biol Chem; 2015 Jan; 290(2):1233-43. PubMed ID: 25451942
[TBL] [Abstract][Full Text] [Related]
5. GLP-1 and GIP receptor signaling in beta cells - A review of receptor interactions and co-stimulation.
Mayendraraj A; Rosenkilde MM; Gasbjerg LS
Peptides; 2022 May; 151():170749. PubMed ID: 35065096
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological characterization of mono-, dual- and tri-peptidic agonists at GIP and GLP-1 receptors.
Yuliantie E; Darbalaei S; Dai A; Zhao P; Yang D; Sexton PM; Wang MW; Wootten D
Biochem Pharmacol; 2020 Jul; 177():114001. PubMed ID: 32360365
[TBL] [Abstract][Full Text] [Related]
7. Human epicardial adipose tissue expresses glucose-dependent insulinotropic polypeptide, glucagon, and glucagon-like peptide-1 receptors as potential targets of pleiotropic therapies.
Malavazos AE; Iacobellis G; Dozio E; Basilico S; Di Vincenzo A; Dubini C; Menicanti L; Vianello E; Meregalli C; Ruocco C; Ragni M; Secchi F; Spagnolo P; Castelvecchio S; Morricone L; Buscemi S; Giordano A; Goldberger JJ; Carruba M; Cinti S; Corsi Romanelli MM; Nisoli E
Eur J Prev Cardiol; 2023 Jun; 30(8):680-693. PubMed ID: 36799940
[TBL] [Abstract][Full Text] [Related]
8. The GIP receptor displays higher basal activity than the GLP-1 receptor but does not recruit GRK2 or arrestin3 effectively.
Al-Sabah S; Al-Fulaij M; Shaaban G; Ahmed HA; Mann RJ; Donnelly D; Bünemann M; Krasel C
PLoS One; 2014; 9(9):e106890. PubMed ID: 25191754
[TBL] [Abstract][Full Text] [Related]
9. Targeting the GIPR for obesity: To agonize or antagonize? Potential mechanisms.
Campbell JE
Mol Metab; 2021 Apr; 46():101139. PubMed ID: 33290902
[TBL] [Abstract][Full Text] [Related]
10. Effects on pancreatic Beta and other Islet cells of the glucose-dependent insulinotropic polypeptide.
Khan R; Tomas A; Rutter GA
Peptides; 2020 Mar; 125():170201. PubMed ID: 31751656
[TBL] [Abstract][Full Text] [Related]
11. Two incretin hormones GLP-1 and GIP: comparison of their actions in insulin secretion and β cell preservation.
Yabe D; Seino Y
Prog Biophys Mol Biol; 2011 Nov; 107(2):248-56. PubMed ID: 21820006
[TBL] [Abstract][Full Text] [Related]
12. Differential effects of glucose-dependent insulinotropic polypeptide receptor/glucagon-like peptide-1 receptor heteromerization on cell signaling when expressed in HEK-293 cells.
Al-Zaid B; Chacko S; Ezeamuzie CI; Bünemann M; Krasel C; Karimian T; Lanzerstorfer P; Al-Sabah S
Pharmacol Res Perspect; 2022 Oct; 10(5):e01013. PubMed ID: 36177761
[TBL] [Abstract][Full Text] [Related]
13. GIP and GLP-1 as incretin hormones: lessons from single and double incretin receptor knockout mice.
Hansotia T; Drucker DJ
Regul Pept; 2005 Jun; 128(2):125-34. PubMed ID: 15780432
[TBL] [Abstract][Full Text] [Related]
14. Genetic and biased agonist-mediated reductions in β-arrestin recruitment prolong cAMP signaling at glucagon family receptors.
Jones B; McGlone ER; Fang Z; Pickford P; Corrêa IR; Oishi A; Jockers R; Inoue A; Kumar S; Görlitz F; Dunsby C; French PMW; Rutter GA; Tan T; Tomas A; Bloom SR
J Biol Chem; 2021; 296():100133. PubMed ID: 33268378
[TBL] [Abstract][Full Text] [Related]
15. Twincretin as a potential therapeutic for the management of type 2 diabetes with obesity.
Usui R; Yabe D; Seino Y
J Diabetes Investig; 2019 Jul; 10(4):902-905. PubMed ID: 30637966
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological antagonism of the incretin system protects against diet-induced obesity.
Svendsen B; Capozzi ME; Nui J; Hannou SA; Finan B; Naylor J; Ravn P; D'Alessio DA; Campbell JE
Mol Metab; 2020 Feb; 32():44-55. PubMed ID: 32029229
[TBL] [Abstract][Full Text] [Related]
17. The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect.
Fisman EZ; Tenenbaum A
Cardiovasc Diabetol; 2021 Nov; 20(1):225. PubMed ID: 34819089
[TBL] [Abstract][Full Text] [Related]
18. Body weight lowering effect of glucose-dependent insulinotropic polypeptide and glucagon-like peptide receptor agonists is more efficient in RAMP1/3 KO than in WT mice.
Leuthardt AS; Boyle CN; Raun K; Lutz TA; John LM; Le Foll C
Eur J Pharmacol; 2023 Sep; 955():175912. PubMed ID: 37454968
[TBL] [Abstract][Full Text] [Related]
19. Recent Advances in Incretin-Based Pharmacotherapies for the Treatment of Obesity and Diabetes.
Tan Q; Akindehin SE; Orsso CE; Waldner RC; DiMarchi RD; Müller TD; Haqq AM
Front Endocrinol (Lausanne); 2022; 13():838410. PubMed ID: 35299971
[TBL] [Abstract][Full Text] [Related]
20. Structural determinants of dual incretin receptor agonism by tirzepatide.
Sun B; Willard FS; Feng D; Alsina-Fernandez J; Chen Q; Vieth M; Ho JD; Showalter AD; Stutsman C; Ding L; Suter TM; Dunbar JD; Carpenter JW; Mohammed FA; Aihara E; Brown RA; Bueno AB; Emmerson PJ; Moyers JS; Kobilka TS; Coghlan MP; Kobilka BK; Sloop KW
Proc Natl Acad Sci U S A; 2022 Mar; 119(13):e2116506119. PubMed ID: 35333651
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
